- Inspire Medical Systems (INSP +5.0%) was initiated with Overweight rating at JPMorgan Chase with price target of $148, an upside of 16.3% from current levels.
- In the past 6 months, the stock has gained 165%; Wall Street Analysts rating is Bullish and it has exceeded the PT, $122.
- Analyst Robbie Marcus believes that the company offers an effective, minimally invasive, and convenient solution for treating obstructive sleep apnea while addressing the shortcomings of existing treatment options.
- He further adds that the company is well positioned to capture "meaningful share" in the $17B U.S. obstructive sleep apnea market opportunity.
- Strong market opportunity exists for an alternative to CPAP that is effective and minimally invasive:
- Previously: Inspire Medical Systems' Inspire therapy to be covered by Humana (Sep 1)